Literature DB >> 21852468

Infectious diseases. Drug developers finally take aim at a neglected disease.

Mitch Leslie.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21852468     DOI： 10.1126/science.333.6045.933

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


× No keyword cloud information.
  21 in total

1.  Design and exploratory data analysis of a second generation of dendrimer prodrugs potentially antichagasic and leishmanicide.

Authors:  Jeanine Giarolla; Kerly Fernanda Mesquita Pasqualoto; Elizabeth I Ferreira
Journal:  Mol Divers       Date:  2013-08-29       Impact factor: 2.943

2.  Dialkylimidazole inhibitors of Trypanosoma cruzi sterol 14α-demethylase as anti-Chagas disease agents.

Authors:  Praveen Kumar Suryadevara; Kishore Kumar Racherla; Srinivas Olepu; Neil R Norcross; Hari Babu Tatipaka; Jennifer A Arif; Joseph D Planer; Galina I Lepesheva; Christophe L M J Verlinde; Frederick S Buckner; Michael H Gelb
Journal:  Bioorg Med Chem Lett       Date:  2013-08-12       Impact factor: 2.823

Review 3.  Design or screening of drugs for the treatment of Chagas disease: what shows the most promise?

Authors:  Galina I Lepesheva
Journal:  Expert Opin Drug Discov       Date:  2013-09-30       Impact factor: 6.098

4.  Complexes of Trypanosoma cruzi sterol 14α-demethylase (CYP51) with two pyridine-based drug candidates for Chagas disease: structural basis for pathogen selectivity.

Authors:  Tatiana Y Hargrove; Zdzislaw Wawrzak; Paul W Alexander; Jason H Chaplin; Martine Keenan; Susan A Charman; Catherine J Perez; Michael R Waterman; Eric Chatelain; Galina I Lepesheva
Journal:  J Biol Chem       Date:  2013-09-18       Impact factor: 5.157

5.  Sterol 14α-Demethylase Structure-Based Optimization of Drug Candidates for Human Infections with the Protozoan Trypanosomatidae.

Authors:  Laura Friggeri; Tatiana Y Hargrove; Girish Rachakonda; Anna L Blobaum; Paxtyn Fisher; Gabriel Melo de Oliveira; Cristiane França da Silva; Maria de Nazaré C Soeiro; W David Nes; Craig W Lindsley; Fernando Villalta; F Peter Guengerich; Galina I Lepesheva
Journal:  J Med Chem       Date:  2018-11-30       Impact factor: 7.446

6.  VNI cures acute and chronic experimental Chagas disease.

Authors:  Fernando Villalta; Mark C Dobish; Pius N Nde; Yulia Y Kleshchenko; Tatiana Y Hargrove; Candice A Johnson; Michael R Waterman; Jeffrey N Johnston; Galina I Lepesheva
Journal:  J Infect Dis       Date:  2013-01-31       Impact factor: 5.226

7.  In vitro and in vivo studies of the antiparasitic activity of sterol 14α-demethylase (CYP51) inhibitor VNI against drug-resistant strains of Trypanosoma cruzi.

Authors:  Maria de Nazaré Correia Soeiro; Elen Mello de Souza; Cristiane França da Silva; Denise da Gama Jaen Batista; Marcos Meuser Batista; Beatriz Philot Pavão; Julianna Siciliano Araújo; Claudia Alessandra Fortes Aiub; Patrícia Bernardino da Silva; Jessica Lionel; Constança Britto; Kwangho Kim; Gary Sulikowski; Tatiana Y Hargrove; Michael R Waterman; Galina I Lepesheva
Journal:  Antimicrob Agents Chemother       Date:  2013-06-17       Impact factor: 5.191

8.  Golgi UDP-GlcNAc:polypeptide O-α-N-Acetyl-d-glucosaminyltransferase 2 (TcOGNT2) regulates trypomastigote production and function in Trypanosoma cruzi.

Authors:  Carolina M Koeller; Hanke van der Wel; Christa L Feasley; Fernanda Abreu; Juliana Dutra Barbosa da Rocha; Fabrício Montalvão; Patrícia Fampa; Flávia C G Dos Reis; Georgia C Atella; Thaís Souto-Padrón; Christopher M West; Norton Heise
Journal:  Eukaryot Cell       Date:  2014-08-01

9.  Cellular response to Trypanosoma cruzi infection induces secretion of defensin α-1, which damages the flagellum, neutralizes trypanosome motility, and inhibits infection.

Authors:  Candice A Johnson; Girish Rachakonda; Yuliya Y Kleshchenko; Pius N Nde; M Nia Madison; Siddharth Pratap; Tatiana C Cardenas; Chase Taylor; Maria F Lima; Fernando Villalta
Journal:  Infect Immun       Date:  2013-08-26       Impact factor: 3.441

10.  Clinical Candidate VT-1161's Antiparasitic Effect In Vitro, Activity in a Murine Model of Chagas Disease, and Structural Characterization in Complex with the Target Enzyme CYP51 from Trypanosoma cruzi.

Authors:  William J Hoekstra; Tatiana Y Hargrove; Zdzislaw Wawrzak; Denise da Gama Jaen Batista; Cristiane F da Silva; Aline S G Nefertiti; Girish Rachakonda; Robert J Schotzinger; Fernando Villalta; Maria de Nazaré C Soeiro; Galina I Lepesheva
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.